Skip to main content

Medicare Reconsiders Coverage for PET Beta Amyloid Imaging in Alzheimer's Disease: A Shift Towards Personalized Care

 Introduction:

As long time readers know, Medicare periodically reviews its national coverage policies for medical services. This includes the consideration of National Coverage Determinations (NCDs) regarding whether specific items or services should be covered nationally. One such NCD pertains to PET beta amyloid imaging for dementia and neurodegenerative disease.



Background:

In 2013, Medicare established the NCD for PET beta amyloid scans as a part of Coverage with Evidence Development (CED) studies. The current NCD allows for coverage of a single PET beta amyloid scan when provided through a clinical trial that has been reviewed and approved by CMS. All other use cases are non-covered.

There has been considerable stakeholder criticism that the NCD was overly restrictive and impacted Medicare beneficiary's ability to access care. However, with advances in medical care, standards of practice, and the development of promising anti-amyloid treatments, the application of amyloid PET scans has evolved.

Shift in Focus:

In response to stakeholder feedback and the availability of new evidence, Medicare is now considering two key questions:

  1. Should the requirement for CED in PET beta amyloid imaging be removed?
  2. Should Medicare remove the current NCD for beta amyloid PET in dementia and neurodegenerative disease?

Advancements in Alzheimer's Care:

The landscape of Alzheimer's disease (AD) care has significantly changed since Medicare finalized its CED coverage for PET Beta Amyloid Imaging in 2013. Treatment approaches now emphasize addressing health risk factors and comorbidities. With the rise in development of anti-amyloid drug treatments showing promise in modifying AD pathophysiology, many have questioned whether the current national policy restricting PET scans would serve as a barrier to these treatments.

Importance of Brain Amyloid Confirmation:

With the introduction of new pharmacological treatments such as Leqembi, confirming the presence of brain amyloid through PET scans has become crucial for appropriate patient selection. This ensures that patients receive treatments tailored to their individual characteristics, reducing the risk of unnecessary treatment harms.

The Role of Local Coverage Determinations:

With its proposed policy, CMS would rescind the national coverage policy and empower local Medicare Administrative Contractors (MACs) with the discretion to make coverage determinations regarding PET beta amyloid imaging. This flexibility allows prompt responses to new evidence on proven treatments for individual patients.

While the Local Coverage Determination process is, in fact, more nimble than the national process it still requires the MACs to review clinical evidence and allow for public notice and comment before they establish any new policy.

Addressing Health Disparities:

AD prevalence varies across racial and ethnic groups, with Blacks and Hispanics having a higher likelihood of AD compared to Whites. However, they are less likely to have a diagnosis due to various factors, including differing beliefs about AD and higher rates of discrimination in dementia healthcare.

Conclusion:

In light of advancements in medical care and the development of new anti-amyloid treatments, Medicare is proposing to remove the NCD for PET beta amyloid imaging. This decision aims to provide more personalized care for AD patients and reduce the burden on providers and patients. By empowering MACs to make coverage determinations, Medicare seeks to adapt to the evolving landscape of Alzheimer's care and address health disparities in dementia research and treatment.

The proposal to remove the NCD and end the provisional CED coverage for PET beta amyloid imaging is open for public comments until August 16, 2023.

Comments

Post a Comment

Popular posts from this blog

FDA Green Light Inches Genetic Screening Forward

The FDA recently granted authorization for the first multi-gene test for assessing hereditary cancer risk, marking a significant advancement in genetic screening capabilities. Developed by Invitae Corporation, the Invitae Common Hereditary Cancers Panel analyzes variants in 47 genes associated with increased cancer risk. Using next-generation sequencing on DNA from blood samples, the test looks at BRCA1 and BRCA2 variants linked to breast and ovarian cancer, as well as other cancer-related genes.  (image source: Adobe Stock Images) The FDA’s approval provides a regulatory framework giving labs a clearer roadmap for developing similar multi-gene panels. With an authorized model in place, labs can proceed more confidently in navigating FDA submissions. Specifically, the de novo classification created for Invitae’s test allows future lab-developed panels to gain regulatory clearance through the expedited 510(k) pathway by demonstrating substantial equivalence. This streamlined validat...
Post a Comment
Read more

Selecting Therapeutic Alternatives: A Critical Perspective for Drug Manufacturers

The Inflation Reduction Act (IRA) of 2022 instructed the Centers for Medicare and Medicaid Services (CMS) to initiate drug price negotiations with manufacturers for the first time. A key component of these negotiations involves considering factors like the drug's benefits and costs to establish a "lowest maximum fair price." (MFP) For drug manufacturers, CMS’s process for making comparisons of therapeutic alternative(s) to determine the MFP raises a number of crucial questions. The IRA's guidance suggests that CMS will initially compare drugs within the same class as the negotiated drug to determine a starting point for pricing. For drug manufacturers, this approach raises concerns regarding price competition within drug classes. As new drugs are often priced in line with preexisting brand-name drugs in the same class, the negotiation process may result in downward pressure on prices for all drugs in the class. This could significantly affect the revenue and profitabi...
Post a Comment
Read more

TCET Pathway Could Accelerate Access to Innovating Technologies

The Centers for Medicare & Medicaid Services (CMS) proposed the Transitional Coverage for Emerging Technologies (TCET) pathway to enable quicker coverage decisions for breakthrough devices needing accelerated regulatory review. As described in JAMA Health Forum, TCET allows tailored oversight based on an innovation’s specific benefits and risks. TCET focuses on FDA Breakthrough-designated devices for serious conditions supported by limited clinical data for market authorization. By facilitating transitional coverage, TCET aims to help make cutting-edge technologies accessible to patients while additional real-world evidence is gathered to meet CMS’ “reasonable and necessary” standard.  For developers to optimize TCET’s streamlined approach they should be sure to: - Pursue FDA Breakthrough designation when criteria are met. This opens the TCET pathway.   - Engage CMS early on study designs and evidence needs. Incorporate draft guidance on endpoints and real-world data....
Post a Comment
Read more